Articolo in rivista, 2022, ENG, 10.3390/app12188990
Srivastava, Ankit; Rikhari, Deeksha; Pradhan, Biswajita; Bharadwaj, Kaushik Kumar; Gaballo, Antonio; Quarta, Alessandra; Jena, Mrutyunjay; Srivastava, Sameer; Ragusa, Andrea
Motilal Nehru Natl Inst Technol; Berhampur Univ; Sangmyung Univ; Guwahati Univ; Inst Nanotechnol; Univ Salento
Neuropeptides are mainly secreted from the human central and peripheral nervous systems. Neuropeptides bind to its cognate rhodopsin-like G-protein coupled receptor (GPCR) and perform various physiological functions. Conventional cancer treatments in clinical practice still present many drawbacks due to the lack of selectivity toward the target cell, drug-resistance, and side-effects, thus pushing for the development of new therapeutic agents and therapies. Recent research suggests that neuropeptides influence cancer cell proliferation, invasion, metastasis, and angiogenesis and, therefore, they could be exploited as a target for novel anticancer therapies. Very recently, targeted approaches that inhibit neuropeptides and their associated receptors are being developed in cancer treatment. This review focuses on various neuropeptides and their potential utility as drug targets by different inhibitors as a recently identified approach to cancer prevention, with particular emphasis on colorectal cancer.
Applied sciences 12 (18)
neuropeptide, receptor, inhibitors, cancer, therapeutic agents, bombesin, neurotensin, vasoactive intestinal peptide, substance P
Gaballo Antonio, Quarta Alessandra
ID: 487736
Year: 2022
Type: Articolo in rivista
Creation: 2023-10-23 15:35:05.000
Last update: 2023-10-23 15:35:05.000
CNR authors
External IDs
CNR OAI-PMH: oai:it.cnr:prodotti:487736
DOI: 10.3390/app12188990
ISI Web of Science (WOS): 000858397300001